7 Primus Biosciences

Executive Summary

7 Primus Biosciences is a private, pre-clinical oncology biotechnology company based in San Diego, founded in 2021. The company leverages proprietary platforms and deep translational expertise to develop advanced cancer therapies, combining cutting-edge scientific discovery with breakthrough technology. With a focus on antibodies, biologics, and small molecules, 7 Primus aims to transform novel insights into effective treatments for patients globally. Despite being early-stage with no disclosed pipeline details or funding history, the company's accomplished team and innovative approach position it as a potential contender in the competitive oncology landscape. However, given the lack of publicly available data on specific programs or financials, the company remains high-risk and early-phase, requiring further validation of its platforms and therapeutic candidates.

Upcoming Catalysts (preview)

• TBDPreclinical Proof-of-Concept Data for Lead Program50% success
• TBDSeries A Financing Round60% success
• TBDStrategic Partnership or Licensing Deal40% success